1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. COMPANION DIAGNOSTICS (CDX) MARKET BY TECHNOLOGY
5.1. Introduction
5.2. Polymerase Chian Reaction (PCR)
5.3. Immunohistochemistry (IHC)
5.4. In-Situ Hybridization (ISH)
5.5. Next-Generation Sequencing (NGS)
6. COMPANION DIAGNOSTICS (CDX) MARKET BY INDICATION
6.1. Introduction
6.2. Lung Cancer
6.3. Breast Cancer
6.4. Colorectal Cancer
6.5. Others
7. COMPANION DIAGNOSTICS (CDX) MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom
7.4.4. Italy
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. Israel
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. Japan
7.6.4. South Korea
7.6.5. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Abbott
9.2. Aglient Technologies Inc.
9.3. Arup Laboratories
9.4. F. Hoffmann-La Roche Ltd
9.5. Illumina, Inc.
9.6. Invivoscribe, Inc
9.7. Myriad Genetics, Inc.
9.8. QIAGEN
9.9. Thermo Fisher Scientific Inc.